Herzuma®
Metastatic breast cancer
MarketedApproved
Key Facts
About Celltrion
Celltrion's mission is to promote patient health by making advanced biologics affordable and accessible globally. It has achieved this by evolving from a contract manufacturer into a vertically integrated powerhouse, becoming the world's leading biosimilar producer with a robust pipeline. Its core strategy leverages massive, FDA/EMA-certified manufacturing capacity, a direct global sales network, and a deep R&D pipeline spanning biosimilars and novel biologics to drive growth and secure long-term market leadership.
View full company profileTherapeutic Areas
Other Metastatic breast cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| ZetaMAST (Zeta-MBC-005) | Zetagen Therapeutics | Phase 2 |
| Platin-DRP® | Chosa Oncology | Validation |
| OP-3136 | Olema Oncology | Preclinical |
| Vectorized-VX-765 | Atlanthera | Research |
| AURORA 2 Project Collaboration | Seqalis | Phase 2 |
| BPI-1178 (Eciruciclib) | Beta Pharma | Phase 3 |
| Eftilagimod alfa (efti) | Immutep | Phase IIb |
| (Z)-endoxifen | Atossa Therapeutics | Phase 1/2 |
| Bria-IMT™ + CPI | BriaCell Therapeutics | Phase 3 |
| Bria-OTS™ (Bria-BRES™) | BriaCell Therapeutics | Phase 1/2 |